Investment Thesis
Processa Pharmaceuticals is a pre-revenue development-stage pharmaceutical company with unsustainable cash burn of $3.6M annually against only $1.7M in cash reserves, indicating less than 6 months of operational runway. With zero revenue generation, $3.3M operating losses, negative ROE (-132.9%) and severe liquidity stress (current ratio 0.98x), the company faces existential risk without successful capital raises or near-term product commercialization.
Strengths
- Minimal debt burden with only $27.5K long-term debt and 0.01x debt-to-equity ratio provides clean balance sheet
- Low capital expenditure requirements ($3.2K) typical of pharmaceutical development-stage companies preserve cash
- Maintains $1.7M in cash reserves for ongoing operations and R&D activities
Risks
- Zero revenue with $3.3M annual operating losses creates unsustainable burn profile
- Operating cash flow of -$3.6M exceeds total cash position, indicating critical liquidity crisis with <6 months runway
- Current ratio of 0.98x signals liquidity stress with current liabilities exceeding current assets
- Negative ROE (-132.9%) and ROA (-74.7%) demonstrate severe shareholder value destruction
- No disclosed revenue-generating products or clear commercialization timeline
- Dependency on capital markets access, clinical trial success, and partnership deals for survival
Key Metrics to Watch
- Monthly cash burn rate relative to remaining cash position and time to funding requirement
- Clinical trial progress, regulatory filings, and FDA pipeline advancement
- Revenue milestones and product commercialization announcements
- Capital raise announcements and cash position extensions
- Strategic partnerships, licensing deals, or acquisition interest
Financial Metrics
Revenue
0.0
Net Income
-3.4M
EPS (Diluted)
$-1.29
Free Cash Flow
-3.6M
Total Assets
4.5M
Cash
1.7M
Profitability Ratios
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
ROE
-132.9%
ROA
-74.7%
FCF Margin
N/A
Balance Sheet & Liquidity
Current Ratio
0.98x
Quick Ratio
0.91x
Debt/Equity
0.01x
Debt/Assets
43.8%
Interest Coverage
-9,202.25x
Long-term Debt
27.5K
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-16T09:53:33.075263 |
Data as of: 2026-03-31 |
Powered by Claude AI